Exome-wide sequencing shows low mutation rates and identifies novel mutated genes in seminomas

European Urology

Volumn 68, Issue 1, 2015, Pages 77-83

  Cutcutache, Ioana ^a   Suzuki, Yuka ^a   Tan, Iain Beehuat ^b,c   Ramgopal, Subhashini ^a   Zhang, Shenli ^a   Ramnarayanan, Kalpana ^a   Gan, Anna ^a,b   Lee, Heng Hong ^a,b   Tay, Su Ting ^a   Ooi, Aikseng ^d   Ong, Choon Kiat ^b   Bolthouse, Jonathan T ^e   Lane, Brian R ^e   Anema, John G ^e   Kahnoski, Richard J ^e   Tan, Patrick ^a,c,f   Teh, Bin Tean ^a,b,f   Rozen, Steven G ^a  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

^e SPECTRUM HEALTH   (United States)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Copy number; Exome sequencing; Germ cell tumor; KIT; KRAS; Somatic mutation; Testicular cancer

Indexed keywords

DNA; K RAS PROTEIN; NUCLEOTIDE; STEM CELL FACTOR RECEPTOR; ADENOSINE TRIPHOSPHATASE; CADHERIN; CASEIN KINASE 2, ALPHA, HUMAN; CASEIN KINASE II; CDH17 PROTEIN, HUMAN; CHD1 PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA HELICASE; KRAS PROTEIN, HUMAN; MCC PROTEIN, HUMAN; NONHISTONE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITOL-3 KINASE REGULATORY SUBUNIT 2, HUMAN; PROTEIN P21; SMARCA5 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLONAL VARIATION; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; EXOME; EXOME WIDE SEQUENCING; GENE DOSAGE; GENE IDENTIFICATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDEL MUTATION; MALE; MICROCHIP ANALYSIS; MUTATION RATE; PRIORITY JOURNAL; SEMINOMA; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TESTIS CANCER; TUMOR VOLUME; ADOLESCENT; CASE CONTROL STUDY; COPY NUMBER VARIATION; GENETICS; MIDDLE AGED; MUTATION; TESTIS TUMOR;

ADENOSINE TRIPHOSPHATASES; ADOLESCENT; ADULT; CADHERINS; CASE-CONTROL STUDIES; CASEIN KINASE II; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA COPY NUMBER VARIATIONS; DNA HELICASES; DNA-BINDING PROTEINS; EXOME; HUMANS; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS P21(RAS); SEMINOMA; SEQUENCE ANALYSIS, DNA; TESTICULAR NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84942983991     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.12.040     Document Type: Article

References (39)

1. Rajpert-De Meyts E. Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update 2006;12:303-23.
2. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 2002;99:4592-5.
3. Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol 1998;16:702-6.
4. Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA. International patterns and trends in testis cancer incidence. Int J Cancer 2005; 115:822-7.
5. Richiardi L, Pettersson A, Akre O. Genetic and environmental risk factors for testicular cancer. Int J Androl 2007;30:230-40.
6. Yaes RJ. Tumor heterogeneity, tumor size, and radioresistance. Int J Radiat Oncol Biol Phys 1989;17:993-1005.
7. Oosterhuis JW, Gillis AJ, van Putten WJ, de Jong B, Looijenga LH. Interphase cytogenetics of carcinoma in situ of the testis. Numeric analysis of the chromosomes 1, 12 and 15. Eur Urol 1993;23:16-21.
8. Looijenga LH, Zafarana G, Grygalewicz B, et al. Role of gain of 12p in germ cell tumour development. APMIS 2003;111:161-71.
9. McIntyre A, Summersgill B, Spendlove HE, Huddart R, Houlston R, Shipley J. Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors. Neoplasia 2005;7:1047-52.
10. Olie RA, Looijenga LH, Boerrigter L, et al. N-And KRAS mutations in primary testicular germ cell tumors: incidence and possible biological implications. Genes Chromosomes Cancer 1995;12:110-6.
11. Bignell G, Smith R, Hunter C, et al. Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Genes Chromosomes Cancer 2006;45:42-6.
12. Goddard NC, McIntyre A, Summersgill B, Gilbert D, Kitazawa S, Shipley J. KIT and RAS signalling pathways in testicular germ cell tumours: new data and a review of the literature. Int J Androl 2007;30:337-48.
13. Coffey J, Linger R, Pugh J, et al. Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. Genes Chromosomes Cancer 2008;47:34-42.
14. Sommerer F, Hengge UR, Markwarth A, et al. Mutations of BRAF and RAS are rare events in germ cell tumours. Int J Cancer 2005;113: 329-35.
15. Biermann K, Goke F, Nettersheim D, et al. c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma. J Pathol 2007;213:311-8.
16. Carter SL, Cibulskis K, Helman E, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012;30: 413-21.
17. Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004;164:305-13.
18. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152:714-26.
19. Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014;25:91-101.
20. Huang S, Gulzar ZG, Salari K, Lapointe J, Brooks JD, Pollack JR. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 2012;31:4164-70.
21. Burkhardt L, Fuchs S, Krohn A, et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res 2013;73:2795-805.
22. Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661-5.
23. Matsumine A, Senda T, Baeg GH, et al. MCC, a cytoplasmic protein that blocks cell cycle progression from the G0/G1 to S phase. J Biol Chem 1996;271:10341-6.
24. Pangon L, Mladenova D, Watkins L, et al. MCC inhibits beta-catenin transcriptional activity by sequestering DBC1 in the cytoplasm. Int J Cancer 2015;136:55-64.
25. Gigek CO, Lisboa LC, Leal MF, et al. SMARCA5 methylation and expression in gastric cancer. Cancer Invest 2011;29:162-6.
26. Helming KC, Wang X, Roberts CW. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell 2014;26:309-17.
27. Zhang J, Liu QS, Dong WG. Blockade of proliferation and migration of gastric cancer via targeting CDH17 with an artificial microRNA. Med Oncol 2011;28:494-501.
28. Qiu HB, Zhang LY, Ren C, et al. Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/beta-catenin signaling. PLoS One 2013;8:e56959.
29. Sun QY, Ding LW, Xiao JF, et al. SETDB1 accelerates tumorigenesis by regulating WNT signaling pathway. J Pathol. In press. http://dx. doi.org/10.1002/path.4482
30. Ceol CJ, Houvras Y, Jane-Valbuena J, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 2011;471:513-7.
31. Lee JK, Kim KC. DZNep, inhibitor of S-Adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells. Biochem Biophys Res Commun 2013;438:647-52.
32. Upadhyaya AB, Lee SH, DeJong J. Identification of a general transcription factor TFIIAalpha/beta homolog selectively expressed in testis. J Biol Chem 1999;274:18040-8.
33. Shigunov P, Sotelo-Silveira J, Stimamiglio MA, et al. Ribonomic analysis of human DZIP1 reveals its involvement in ribonucleoprotein complexes and stress granules. BMC Mol Biol 2014;15:12.
34. Geisinger A, Dos Santos A, Benavente R, Wettstein R. Identification and characterization of SRSP1, a rat gene differentially expressed during spermatogenesis and coding for a serine stretch-containing protein. Cytogenet Genome Res 2002;98:249-54.
35. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr. LA, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
36. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 2007;92:1519-32.
37. Gerber N, Mynarek M, von Hoff K, Friedrich C, Resch A, Rutkowski S. Recent developments and current concepts in medulloblastoma. Cancer Treat Rev 2014;40:356-65.
38. Salzer W, Devidas M, Carroll W, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia 2009;24:355-70.
39. Ruf CG, Port M, Schmelz HU, et al. Clinically apparent and occult metastasized seminoma: almost indistinguishable on the transcriptional level. PLoS One 2014;9:e95009.